Brief description not available

Researchers at the University of California, Davis have developed novel antisense oligonucleotide (ASO) therapies that enhance ADNP protein expression to address haploinsufficiency in ADNP syndrome.

Chronic wounds affect over 6.5 million people in the United States costing more than $25B annually. 23% of military blast and burn wounds do not close, affecting a military patient's bone, skin, nerves. Moreover, 64% of military trauma have abnormal bone growth into soft tissue. Slow healing of recalcitrant wounds is a known and persistent problem, with incomplete healing, scarring, and abnormal tissue regeneration. Precise control of wound healing depends on physician's evaluation, experience. Physicians generally provide conditions and time for body to either heal itself, or to accept and heal around direct transplantations, and their practice relies a lot on passive recovery. And while newer static approaches have demonstrated enhanced growth of non-regenerative tissue, they do not adapt to the changing state of wound, thus resulting in limited efficacy.

Researchers at the University of California, Davis have engineered dominant negative CD40L mutant polypeptides that inhibit CD40/CD40L-mediated signaling, offering therapeutic potential for inflammatory, immune disorders, and cancer with improved safety profiles.

POEM is a groundbreaking 3D bioprinting technology enabling high-resolution, multi-material, and cell-laden structure fabrication with enhanced cell viability.

This technology offers a novel approach to treating epilepsy by preventing the spread of epileptic networks and improving memory deficits through targeted electrical stimulation.

A revolutionary method for improving the efficiency and quality of reprogramming adult cells into stem cells or other therapeutically relevant cell types via adhesome gene manipulation.

This technology represents a groundbreaking approach to treating Primary Open Angle Glaucoma by directly targeting the trabecular meshwork pathology with lipid nanoparticle-mediated delivery of gene editing tools or anti-sense oligos.

Researchers at the University of California, Davis have developed technology that provides an advanced system for monitoring and supporting patient resuscitation and mechanical ventilation, enhancing clinical decision-making.

A novel approach to significantly enhance vancomycin's effectiveness against drug-resistant pathogens by conjugating it with a minimal teixobactin pharmacophore.

Innovative cell lines enabling precise genetic modifications to advance research in gene function, disease modeling, and potential therapeutic interventions.

A revolutionary drug modality for the selective modification and degradation of intracellular proteins in lysosomes.

Site-selective covalent modification of proteins is key to the development of new biomaterials, therapeutics, and other biological tools. As examples in the biomedical field, these techniques have been applied to the construction of antibody-drug conjugates, bispecific cell engagers, and targeted protein therapies, among other applications. While many bioconjugation strategies, such as azide-alkyne cycloaddition or thiol-maleimide coupling, have become widely adopted, the improvement of existing techniques is a highly active area of chemical biology research, as is the development of new synthetic applications of these methods. Key focuses of such efforts include increasing reaction efficiency and ease, balancing selectivity with tag size, and expanding the modification options beyond traditional cysteine and lysine residues. UC Berkeley researchers have developed compounds and methods using tyrosinase to couple small-molecule dithiols to tyrosine-tagged proteins, which effectively introduces a free thiol handle and provides a convenient method to bypass genetic incorporation of cysteine residues for bioconjugation. These newly thiolated proteins were then coupled to maleimide probes as well as other tyrosine-tagged proteins. The researchers were also able to conjugate targeting proteins to drugs, fluorescent probes, and therapeutic enzymes. This easy method to convert accessible tyrosine residues on proteins to thiol tags extends the use of tyrosinase-mediated oxidative coupling to a broader range of protein substrates. 

A novel method for selectively targeting and modulating brain border-associated myeloid cells for the treatment of neurological disorders.

A cutting-edge vaccine delivery platform that enhances tumor treatment by co-delivering MHC class I and II restricted antigens.

Brief description not available

A groundbreaking method for the efficient isolation and preservation of high-purity small extracellular vesicles (sEVs - exosomes) from biofluids using a novel EXO-PEG-TR reagent.

This technology introduces a novel class of synthetic genetic polymers, capable of enhancing protein target binding and mimicking antibodies, for therapeutic and diagnostic applications.

An innovative small molecules therapy that significantly lowers intraocular pressure in glaucoma patients, offering neuroprotection and addressing trabecular meshwork fibrosis.

This technology offers a significant improvement in the therapeutic application of type E botulinum neurotoxin (BoNT/E) by introducing rationally designed mutations into the receptor binding domain.

IS110 family transposons encode a protein component (also referred to as the transposase) and a non coding RNA component (also referred to as the bridgeRNA or bRNA). In its naturally occurring context, a bRNA-bound transposase directs the integration of its cognate transposon (also referred to as the donor) into target DNA sites. The nucleic acid sequence and structure of the bRNA partially determines the sequence identify of the terminal ends of the mobilized donor, and the sequence identify of the target DNA molecule (also referred to as the target or target DNA). UC Berkeley researchers have developed a programmable gene editing technology based on IS110 family transposons that can be used for targeted insertions, deletions, excisions, inversions, replacements, and capture of DNA in vitro and in vivo. Additionally, this technology can be multiplexed to achieve complex assembles of multiple fragments of DNA.

Most tumors are extremely complex, having many oncogene drivers and are, therefore, not as amenable to a CRISPR-mediated therapies. Pediatric low-grade glioma (pLGG) is a type of brain cancer that arises during childhood. Some interventions exist, including surgery and inhibitor drugs, but there is no cure for pLGG. In contrast to most types of cancer (which feature a host of driver oncogenes), pLGG tumors tend to arise due to a single driver oncogene mutation. This aspect makes pLGG a potential target for a genome editing intervention. Because CRISPR enzymes can precisely discriminate between wild-type and mutant sequences in a single cell, enzymes such as Cas9 can target a mutant oncogene site without impacting the corresponding wild-type locus in a non-cancer cell. UC Berkeley researchers have developed a CRISPR-based strategies for anti-cancer genome editing.  The invention consists of a suite of genome editing strategies with the capacity to selectively inactivate the oncogene underlying tumor pathology, for example, mutations in pLGG. Deployed via a delivery strategy with the capacity for broad genome editing of brain cells, our strategy will have the capacity to halt – and potentially reverse – tumor growth.

A novel antimicrobial approach combining pore-forming agents with histones to eradicate bacteria and bypass known resistance mechanisms.

SUMO inhibitors offer a promising new therapy for protecting against cardiac rhythm disturbances and pump failure associated with heart attacks.

Researchers at the University of California, Davis have developed a technology that targets CD147 to significantly improve bone health and treat musculoskeletal diseases without the side effects of current therapies.